Prostate cancer: Comparison of retrograde urethrography and computed tomography in radiotherapy planning

1994 ◽  
Vol 29 (5) ◽  
pp. 1119-1123 ◽  
Author(s):  
Janel A. Cox ◽  
Ronald J. Zagoria ◽  
Milton Raben
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Radiotherapy Planning ◽  
Retrograde Urethrography

Uncertainty in organ delineation using low-dose computed tomography images with high-strength iterative reconstruction technique in radiotherapy for prostate cancer

2021 ◽  
pp. 1-7
Author(s):  
Tsukasa Yoshida ◽  
Tetsuya Tomida ◽  
Atsushi Urikura ◽  
Yuki Aoyama ◽  
Yoichiro Hosokawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Iterative Reconstruction ◽  
Low Dose ◽  
High Strength ◽  
Ct Images ◽  
Seminal Vesicles ◽  
Radiotherapy Planning ◽  
Observer Variability ◽  
Low Dose Computed Tomography

Abstract Introduction This study aimed to investigate the uncertainty in organ delineation of low-dose computed tomography (CT) images using a high-strength iterative reconstruction (IR) during radiotherapy planning for the treatment of prostate cancer. Methods Two CT datasets were prepared with different dose levels by adjusting the reconstruction slice thickness. Two observers independently delineated the prostate, seminal vesicles, bladder and rectum on both images without referring to other modality images. The delineated organ volumes were compared between both images. Observer delineation variability was assessed using Dice similarity coefficient (DSC) and mean distance to agreement. Results No significant differences regarding the delineated organ volumes were observed between the low- and standard-dose images for all organs. Regarding inter-observer variability, the DSC was relatively high for both images, whereas mean distance to agreement was not significantly different between images (p > 0·05 for all). Intra-observer variability for each observer showed high DSC (>0·8 and >0·9 for seminal vesicles and other organs, respectively) but no significant differences in the mean distance to agreement (p > 0·05 for all). Conclusions Our results indicate that low-dose CT images with high-strength IR would be available for organ delineation in the radiotherapy treatment planning for prostate cancer.

Computerized Tomography (CT) Updates and Challenges in Diagnosis of Bone Metastases During Prostate Cancer

2020 ◽  
Vol 16 (5) ◽  
pp. 565-571
Author(s):  
Jinguo Zhang ◽  
Guanzhong Zhai ◽  
Bin Yang ◽  
Zhenhe Liu
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Bone Metastases ◽  
Computerized Tomography ◽  
Single Photon ◽  
Photon Emission ◽  
Major Complication ◽  
Tracer Uptake ◽  
Emission Computed Tomography ◽  
Pet Ct

Prostate cancer is one of the most common cancers in men. This cancer is often associated with indolent tumors with little or no lethal potential. Some of the patients with aggressive prostate cancer have increased morbidity and early deaths. A major complication in advanced prostate cancer is bone metastasis that mainly results in pain, pathological fractures, and compression of spinal nerves. These complications in turn cause severe pain radiating to the extremities and possibly sensory as well as motor disturbances. Further, in patients with a high risk of metastases, treatment is limited to palliative therapies. Therefore, accurate methods for the detection of bone metastases are essential. Technical advances such as single-photon emission computed tomography/ computed tomography (SPECT/CT) have emerged after the introduction of bone scans. These advanced methods allow tomographic image acquisition and help in attenuation correction with anatomical co-localization. The use of positron emission tomography/CT (PET/CT) scanners is also on the rise. These PET scanners are mainly utilized with 18F-sodium-fluoride (NaF), in order to visualize the skeleton and possible changes. Moreover, NaF PET/CT is associated with higher tracer uptake, increased target-to-background ratio and has a higher spatial resolution. However, these newer technologies have not been adopted in clinical guidelines due to lack of definite evidence in support of their use in bone metastases cases. The present review article is focused on current perspectives and challenges of computerized tomography (CT) applications in cases of bone metastases during prostate cancer.

OC-0208: Comparison between 68Ga-PSMA-PET/CT and mpMRI for radiotherapy planning in primary prostate cancer

2020 ◽  
Vol 152 ◽  
pp. S104
Author(s):  
S. Spohn ◽  
C. Jaegle ◽  
A.S. Bettermann ◽  
S. Kiefer ◽  
C.A. Jilg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiotherapy Planning ◽  
Primary Prostate Cancer ◽  
Psma Pet ◽  
Pet Ct

scholarly journals 18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 304
Author(s):  
Giuseppina Biscontini ◽  
Cinzia Romagnolo ◽  
Chiara Cottignoli ◽  
Andrea Palucci ◽  
Fabio Massimo Fringuelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Meta Analysis ◽  
False Negative ◽  
Final Analysis ◽  
Emission Tomography ◽  
True Negative ◽  
Positron Emission ◽  
Pet Ct

Background: to explore the diagnostic accuracy of 18F-Fluciclovine positron-emission tomography (PET) in prostate cancer (PCa), considering both primary staging prior to radical therapy, biochemical recurrence, and advanced setting. Methods: A systematic web search through Embase and Medline was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies performed from 2011 to 2020 were evaluated. The terms used were “PET” or “positron emission tomography” or “positron emission tomography/computed tomography” or “PET/CT” or “positron emission tomography-computed tomography” or “PET-CT” and “Fluciclovine” or “FACBC” and “prostatic neoplasms” or “prostate cancer” or “prostate carcinoma”. Only studies reporting about true positive (TP), true negative (TN), false positive (FP) and false negative (FN) findings of 18F-fluciclovine PET were considered eligible. Results: Fifteen out of 283 studies, and 697 patients, were included in the final analysis. The pooled sensitivity for 18F-Fluciclovine PET/CT for diagnosis of primary PCa was 0.83 (95% CI: 0.80–0.86), the specificity of 0.77 (95% CI: 0.74–0.80). The pooled sensitivity for preoperative LN staging was 0.57 (95% CI: 0.39–0.73) and specificity of 0.99 (95% CI: 0.94–1.00). The pooled sensitivity for the overall detection of recurrence in relapsed patients was 0.68 (95% CI: 0.63–0.73), and specificity of 0.68 (95% CI: 0.60–0.75). Conclusion: This meta-analysis showed promising results in term of sensitivity and specificity for 18F-Fluciclovine PET/CT to stage the primary lesion and in the assessment of nodal metastases, and for the detection of PCa locations in the recurrent setting. However, the limited number of studies and the broad heterogeneity in the selected cohorts and in different investigation protocols are limitation affecting the strength of these results.

Anatomically robust proton therapy using multiple planning computed tomography scans for locally advanced prostate cancer

2021 ◽  
Vol 60 (5) ◽  
pp. 598-604
Author(s):  
Kia Busch ◽  
Benjamin Dahl ◽  
Stine E. Petersen ◽  
Heidi S. Rønde ◽  
Lise Bentzen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Proton Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Locally Advanced Prostate Cancer ◽  
Computed Tomography Scans
Sign in / Sign up

Export Citation Format

Share Document